[Form 4] Crinetics Pharmaceuticals, Inc. Insider Trading Activity
Crinetics Pharmaceuticals (CRNX) reporting person Dana Pizzuti executed option exercises and open-market sales on 10/01/2025. The Form 4 shows a stock option exercise for 5,000 shares at an exercise price of $16.89, creating 5,000 underlying shares. The same day, 5,000 shares were sold in open-market transactions under a Rule 10b5-1 trading plan at a volume-weighted average price of $41.81 (range $41.34–$42.16). Following the reported transactions, the reporting person directly owned 66,270 shares. The filer corrected a prior Form 4 that had misstated post-transaction ownership as 96,270 shares; the correction clarifies the true direct ownership.
Crinetics Pharmaceuticals (CRNX) persona di segnalazione Dana Pizzuti ha eseguito esercizi di opzioni e vendite in mercato aperto il 10/01/2025. Il Modulo 4 mostra un esercizio di opzione su azioni per 5.000 titoli a un prezzo di esercizio di $16,89, generando 5.000 azioni sottostanti. Nello stesso giorno, 5.000 azioni sono state vendute in operazioni di mercato aperto nell'ambito di un piano di trading Rule 10b5-1 a un prezzo medio ponderato per volume di $41,81 (intervallo $41,34–$42,16). A seguito delle transazioni riportate, la persona di segnalazione deteneva direttamente 66.270 azioni. Il compilatore ha corretto un precedente Form 4 che aveva dichiarato erroneamente la proprietà post-transazione come 96.270 azioni; la correzione chiarisce la reale proprietà diretta.
Crinetics Pharmaceuticals (CRNX) persona reportante Dana Pizzuti ejecutó ejercicios de opciones y ventas en el mercado abierto el 10/01/2025. El Formulario 4 muestra un ejercicio de opción sobre acciones de 5,000 a un precio de ejercicio de $16.89, creando 5.000 acciones subyacentes. Ese mismo día, se vendieron 5.000 acciones en transacciones de mercado abierto bajo un plan de negociación Rule 10b5-1 con un precio medio ponderado por volumen de $41.81 (rango $41.34–$42.16). Tras las transacciones reportadas, la persona reportante poseía directamente 66,270 acciones. El presentador corrigió un Formulario 4 anterior que había indicado incorrectamente la propiedad posterior a la transacción como 96.270 acciones; la corrección aclara la verdadera propiedad directa.
Crinetics Pharmaceuticals (CRNX) 보고인 다나 피줄리이 옵션 행사와 공개시장 매도을 2025-10-01에 실행했습니다. 양식 4는 5,000주에 대한 주식 옵션 행사를 행사 가격 $16.89로 보여 주며 5,000주가 기초 주식으로 만들어집니다. 같은 날, 5,000주가 매도되었으며, 규칙 10b5-1 거래 계획에 따라 거래량 가중 평균가 $41.81로 이루어졌고 범위는 $41.34–$42.16입니다. 보고된 거래 이후 보고인은 직접적으로 66,270주를 보유했습니다. 보고인은 거래 후 소유를 96,270주로 잘못 기재한 이전 Form 4를 수정했으며, 수정은 진정한 직접 소유를 명확히 합니다.
Crinetics Pharmaceuticals (CRNX) personne rapportante Dana Pizzuti a exécuté des exercices d’options et des ventes sur le marché libre le 10/01/2025. Le Formulaire 4 affiche un exercice d’options d’actions sur 5 000 titres à un prix d’exercice de $16,89, créant 5 000 actions sous-jacentes. Le même jour, 5 000 actions ont été vendues dans des transactions sur le marché libre dans le cadre d’un plan de négociation Rule 10b5-1 à un prix moyen pondéré en fonction du volume de $41,81 (plage $41,34–$42,16). À la suite des transactions rapportées, la personne rapportante détenait directement 66 270 actions. Le déclarant a corrigé un Formulaire 4 antérieur qui avait indiqué à tort une propriété post-transaction de 96 270 actions; la correction précise la véritable propriété directe.
Crinetics Pharmaceuticals (CRNX) meldende Person Dana Pizzuti hat Optionsausübungen und Verkäufe am freien Markt am 10/01/2025 durchgeführt. Das Formular 4 zeigt eine Ausübung einer Aktienoption über 5.000 Stück zu einem Ausübungspreis von $16,89, wodurch 5.000 zugrunde liegende Aktien geschaffen werden. Am selben Tag wurden 5.000 Aktien in freien Markttransaktionen unter einem Handelsplan nach Regel 10b5-1 zu einem volumenindizierten Durchschnittspreis von $41,81 (Spanne $41,34–$42,16) verkauft. Nach den gemeldeten Transaktionen hielt die meldende Person direkt 66.270 Aktien. Der Einreicher korrigierte ein vorheriges Form 4, das den Besitz nach der Transaktion fälschlicherweise mit 96.270 Aktien angegeben hatte; die Korrektur klärt den tatsächlichen direkten Besitz auf.
شركة Crinetics Pharmaceuticals (CRNX) كشفت الشخص المبلغ دانا بيتسوتي عن تنفيذ تمارين خيارات ومبيعات في السوق المفتوح في 10/01/2025. يظهر النموذج 4 تمرين خيار أسهم لـ 5,000 سهم بسعر تنفيذ $16.89، مما أوجد 5,000 سهم أساسي. في اليوم نفسه، تم بيع 5,000 سهم في معاملات السوق المفتوح بموجب خطة تداول القاعدة 10b5-1 عند سعر متوسط وزني حجمي قدره $41.81 (نطاق $41.34–$42.16). عقب المعاملات المبلغ عنها، امتلك الشخص المبلغ مباشرة 66,270 سهمًا. صحح المقدم نموذج Form 4 سابقًا والذي كان قد ذكر الملكية بعد الصفقة بمقدار 96,270 سهمًا؛ التعديل يوضح الملكية المباشرة الصحيحة.
Crinetics Pharmaceuticals (CRNX) 报告人 Dana Pizzuti 于 2025/10/01 执行了期权行使和在公开市场的出售。 Form 4 显示 5,000 股的股票期权行使，行使价为 $16,89，产生了 5,000 股基础股。 同日，在公开市场交易中以规则 10b5-1 计划进行的交易出售了 5,000 股，成交量加权平均价为 $41,81（区间 $41,34–$42,16）。在报告的交易之后，报告人直接拥有 66,270 股。 申报人纠正了一个先前的 Form 4，该表述的交易后持股为 96,270 股的说法；该更正澄清了真实的直接所有权。
- Adopted Rule 10b5-1 plan execution for the sale on 10/01/2025, indicating pre-planned transactions
- Option exercise of 5,000 shares at $16.89, establishing shares without relying solely on open-market purchases
- Correction to prior Form 4 required: prior filing misstated post-transaction ownership as 96,270 instead of 66,270
- Sale of 5,000 shares reduced direct holdings to 66,270, a disclosure investors may view as insider liquidity
Insights
Insider exercised options and sold an equal number of shares under a Rule 10b5-1 plan on 10/01/2025.
The reporting person exercised a 5,000-share option at $16.89, creating immediate beneficial ownership and then sold 5,000 shares in open-market trades at a $41.81 VWAP under a pre-existing Rule 10b5-1 plan. This sequence (exercise then sale) is a routine liquidity event where proceeds likely exceed the exercise cost on the disclosed prices.
The filing also corrects an earlier reporting error that overstated post-transaction ownership as 96,270 shares; the corrected post-transaction direct holding is 66,270 shares, which is important for accurate insider ownership records and disclosure compliance.
Crinetics Pharmaceuticals (CRNX) persona di segnalazione Dana Pizzuti ha eseguito esercizi di opzioni e vendite in mercato aperto il 10/01/2025. Il Modulo 4 mostra un esercizio di opzione su azioni per 5.000 titoli a un prezzo di esercizio di $16,89, generando 5.000 azioni sottostanti. Nello stesso giorno, 5.000 azioni sono state vendute in operazioni di mercato aperto nell'ambito di un piano di trading Rule 10b5-1 a un prezzo medio ponderato per volume di $41,81 (intervallo $41,34–$42,16). A seguito delle transazioni riportate, la persona di segnalazione deteneva direttamente 66.270 azioni. Il compilatore ha corretto un precedente Form 4 che aveva dichiarato erroneamente la proprietà post-transazione come 96.270 azioni; la correzione chiarisce la reale proprietà diretta.
Crinetics Pharmaceuticals (CRNX) persona reportante Dana Pizzuti ejecutó ejercicios de opciones y ventas en el mercado abierto el 10/01/2025. El Formulario 4 muestra un ejercicio de opción sobre acciones de 5,000 a un precio de ejercicio de $16.89, creando 5.000 acciones subyacentes. Ese mismo día, se vendieron 5.000 acciones en transacciones de mercado abierto bajo un plan de negociación Rule 10b5-1 con un precio medio ponderado por volumen de $41.81 (rango $41.34–$42.16). Tras las transacciones reportadas, la persona reportante poseía directamente 66,270 acciones. El presentador corrigió un Formulario 4 anterior que había indicado incorrectamente la propiedad posterior a la transacción como 96.270 acciones; la corrección aclara la verdadera propiedad directa.
Crinetics Pharmaceuticals (CRNX) 보고인 다나 피줄리이 옵션 행사와 공개시장 매도을 2025-10-01에 실행했습니다. 양식 4는 5,000주에 대한 주식 옵션 행사를 행사 가격 $16.89로 보여 주며 5,000주가 기초 주식으로 만들어집니다. 같은 날, 5,000주가 매도되었으며, 규칙 10b5-1 거래 계획에 따라 거래량 가중 평균가 $41.81로 이루어졌고 범위는 $41.34–$42.16입니다. 보고된 거래 이후 보고인은 직접적으로 66,270주를 보유했습니다. 보고인은 거래 후 소유를 96,270주로 잘못 기재한 이전 Form 4를 수정했으며, 수정은 진정한 직접 소유를 명확히 합니다.
Crinetics Pharmaceuticals (CRNX) personne rapportante Dana Pizzuti a exécuté des exercices d’options et des ventes sur le marché libre le 10/01/2025. Le Formulaire 4 affiche un exercice d’options d’actions sur 5 000 titres à un prix d’exercice de $16,89, créant 5 000 actions sous-jacentes. Le même jour, 5 000 actions ont été vendues dans des transactions sur le marché libre dans le cadre d’un plan de négociation Rule 10b5-1 à un prix moyen pondéré en fonction du volume de $41,81 (plage $41,34–$42,16). À la suite des transactions rapportées, la personne rapportante détenait directement 66 270 actions. Le déclarant a corrigé un Formulaire 4 antérieur qui avait indiqué à tort une propriété post-transaction de 96 270 actions; la correction précise la véritable propriété directe.
Crinetics Pharmaceuticals (CRNX) meldende Person Dana Pizzuti hat Optionsausübungen und Verkäufe am freien Markt am 10/01/2025 durchgeführt. Das Formular 4 zeigt eine Ausübung einer Aktienoption über 5.000 Stück zu einem Ausübungspreis von $16,89, wodurch 5.000 zugrunde liegende Aktien geschaffen werden. Am selben Tag wurden 5.000 Aktien in freien Markttransaktionen unter einem Handelsplan nach Regel 10b5-1 zu einem volumenindizierten Durchschnittspreis von $41,81 (Spanne $41,34–$42,16) verkauft. Nach den gemeldeten Transaktionen hielt die meldende Person direkt 66.270 Aktien. Der Einreicher korrigierte ein vorheriges Form 4, das den Besitz nach der Transaktion fälschlicherweise mit 96.270 Aktien angegeben hatte; die Korrektur klärt den tatsächlichen direkten Besitz auf.
FAQ
What insider transactions did CRNX reporting person Dana Pizzuti disclose?
How many shares does Dana Pizzuti own after the transactions in the Form 4?
Why was a correction filed to a prior Form 4 for CRNX?
At what prices were the shares sold and what was the price range?
Was the sale discretionary or pre-planned?
